Partnerships allow us to leverage complementary skills, technologies and areas of expertise. Through these relationships, we accelerate and enhance how we discover, develop and deliver our therapies to patients. In many instances we have collaborated on multiple projects with partners, often over many years — as we work to sustain collaborations that are successful and mutually beneficial.

Biogen’s collaboration with Eisai on therapeutics for Alzheimer’s disease (AD) has strengthened the pipelines of both companies. Through our agreement, Biogen and Eisai will codevelop and cocommercialize two of Eisai’s product candidates for AD, while Eisai has the option to codevelop and cocommercialize two of Biogen’s AD product candidates. Eisai’s therapeutics have the potential to reduce the Aß plaques that form in the brains of patients, as well as to slow the formation of new plaques, potentially improving symptoms and suppressing disease progression.

In 2013, we announced our fourth collaboration with ISIS Pharmaceuticals. This most recent initiative combines Biogen’s expertise in neurology with ISIS’s leadership in antisense technology. The goal is to leverage antisense technology in advancing the treatment of neurological diseases, including myotonic dystrophy type 1 (the most common form of muscular dystrophy in adults) and spinal muscular atrophy (SMA) in children.

Under our agreement with Adimab, we have licensed its proprietary discovery platform, allowing us to accelerate our efforts in finding the next generation of antibodies to treat neurodegenerative and autoimmune diseases.

Since 2012 Samsung Biologics and Biogen have collaborated through Samsung Bioepis Co., Ltd., a joint venture to develop, manufacture and market biosimilars. The strategic collaboration between the two companies has enabled Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars. At the end of 2013, Biogen announced that it had entered into an agreement with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis, psoriasis and Crohn’s disease.

Biogen is exploring gene-editing therapies for serious, inherited hematological diseases through its collaboration with Sangamo BioSciences. The agreement enables Biogen to enhance our expertise in nonmalignant hematology by leveraging Sangamo’s proprietary genome-editing technology platform to develop treatments targeting sickle cell disease (SCD) and beta-thalassemia.

Biogen’s collaboration with BioFocus, a subsidiary of Galapagos NV, advances our efforts to discover therapies for immunological diseases. This collaboration specifically focuses on identifying and validating novel targets in scleroderma, an autoimmune disease that causes hardening of the skin and can also impact organs.